Article Text
Commentary
MISTIE III: a big step in the right direction
Statistics from Altmetric.com
Footnotes
Competing interests CPK has received an educational grant from Penumbra. ASA receives research support and is a consultant for Penumbra. MB is a consultant for Rebound Therapeutics. DF receives research support from Penumbra. JM receives research support from Penumbra and is an investor and consultant for Rebound Therapeutics.
Provenance and peer review Commissioned; externally peer reviewed.
Patient consent for publication Not required.